GTx Inc. has partnered with Merck and Co. Inc. in a deal worth at least $500 million to develop and commercialize selective androgen receptor modulators (SARMs), a new class of drugs that target musculoskeletal conditions, such as age-related muscle loss. (BioWorld Today)

GTx Inc. has partnered with Merck and Co. Inc. in a deal worth at least $500 million to develop and commercialize selective androgen receptor modulators (SARMs), a new class of drugs that target musculoskeletal conditions, such as age-related muscle loss. (BioWorld Today)

Novacea Inc. and its partner Schering-Plough Corp. halted a Phase III trial of an investigational prostate cancer treatment because of a higher rate of deaths in patients receiving the drug, the firms said Monday. (BioWorld Today)

Novacea Inc. and its partner Schering-Plough Corp. halted a Phase III trial of an investigational prostate cancer treatment because of a higher rate of deaths in patients receiving the drug, the firms said Monday. (BioWorld Today)